Pharma companies spend $475 million to $830 million on launch-related activities. When launches fail to meet expectations, companies destroy significant value, erode brand equity, and deprive patients of treatments that can improve their lives.

Why do promising new therapies underperform at launch?

Four commercial reasons stand out:

• Market-access barriers: 30%
• Lack of patient insights: 27%
• Weak differentiation: 26%
• Stakeholder misalignment: 13%

External factors are responsible for the remainder of the failures.

Market access is often the most critical factor.

If patients cannot access therapy, they will not use it. High copays, prior authorization requirements, narrow coverage criteria, and reimbursement delays can stifle demand, even when physicians are aware of a product’s clinical benefits.

Case in point: PCSK9 cholesterol-lowering therapies. Despite their clinically significant impact on LDL cholesterol levels, high list prices—nearing $14,000 per year at launch—led many payers to institute restrictive formulary policies. Physicians submitted prescriptions that were denied. Patients dropped out of treatment. Sales suffered.

It took significant price cuts and removal of access barriers to improve uptake.

The patient journey is part of the product.

Too many launch teams view the patient journey through the lens of communications and education. In fact, it is a vital component of every launch strategy. From diagnosis to sustained use, patients can face numerous obstacles. They may struggle to see a specialist, obtain insurance coverage, travel to a hospital or infusion center, manage side effects, or understand why they need to stay on therapy. Each of these barriers can dampen initiation and adherence rates, derailing launch performance.

Consider Nerlynx, a HER2-positive breast cancer medication. Nerlynx addressed a clear clinical need. But many patients experienced severe gastrointestinal side effects that led them to stop treatment. Physicians and patients were ill-equipped to prevent or manage these effects ahead of time, causing sales to lag.

Prevention always starts with understanding how patients encounter and engage with therapies across multiple channels. Patient education, prophylactic treatment, and adherence support could have minimized discontinuation due to gastrointestinal side effects.

Clinical data is just one part of differentiation.

When faced with multiple treatment options, physicians typically reach for medicines they know and trust. Positive trial results are not enough to change prescribing habits. Successful launches require clear answers to three questions:

1. Why should physicians prescribe your product?
2. Why should payers cover your product?
3. Why should patients want to use your product?

Answers to these questions will differ by stakeholder. Physicians may care about clinical efficacy, safety profile, and dosing convenience. Payers may prioritize comparative efficacy, budget impact, and avoided costs. Patients may value symptom improvement, convenience, side effects, and quality of life.

An effective value proposition distills clinical data into benefits that resonate with each stakeholder group. Additionally, it requires consistent messaging across publications, field teams, medical education programs, digital platforms, and patient services.

Here are five priorities that can help companies improve launch performance.

1ne. Start market-access planning before launch

Successful market access begins during drug development, not after a product receives regulatory approval. Key messages, endpoints, health-economic data, and pricing assumptions should be validated with payers throughout Phase II and Phase III clinical trials.

Manufacturers can also establish flexible risk-sharing mechanisms in advance, including bridge programs, patient-assistance funds, outcomes-based agreements, and more.

2wo. Align the organization around a shared vision for launch

Launch plans should be developed using a common dataset drawn from clinical development, market access, medical affairs, commercial, regulatory, and patient-support teams. External stakeholders should be engaged early and often.

Medical affairs can validate positioning and identify educational priorities. Market-access intelligence should inform financial forecasting and field training. Patient insights should define support services and key messaging.

Working in silos wastes resources and propagates misaligned expectations. Collaborating too little increases the risk that assumptions will be challenged after launch.

The other issue plaguing product launches is poor hiring decisions based on fit rather than knowledge. Too many organizations would rather hire robots to go out and do rather than people who ask intelligent questions, which many managers take as pushback.

3hree. Understand the patient journey from symptoms to treatment

Commercial organizations must understand the patient journey from symptom onset through diagnosis, referral, coverage, treatment initiation, and maintenance. Preferably, companies should do this before launch.

This insight should then be translated into programs to support patients wherever they encounter hurdles. Solutions may include patient navigators, financial assistance programs, nurse helplines, side-effect education, adherence initiatives, or better referral processes.

4our. Develop a differentiated value story and test it with key audiences

From pricing to patient support, differentiation should be stress-tested with external stakeholders before launch day. If your organization cannot clearly articulate why physicians should prescribe the product, payers should cover it, and patients should use it — chances are you either need more data or a better story.

Keep in mind that more communication is not always the solution. It is about driving behavior change by providing each stakeholder with a relevant reason to change.

5ive. Execute with flexibility and learn as you go

Finally, successful launches require flexibility. Teams should track awareness, prescribing, fulfillment rates, access delays, and patient drop-off from diagnosis through the first year of treatment. When performance falls short, teams should investigate root causes and implement countermeasures.

Similarly, digital, remote, and field-based engagement should work together seamlessly. Messaging may differ by channel and stakeholder, but the underlying data should always be current. Companies should reach customers where they are willing and able to engage, while leveraging the strongest available evidence to personalize that experience.

Learn from reality.

Commercial excellence starts with asking hard questions about how the science applies to reimbursement, clinical care, and patients’ day-to-day realities. It requires launching with a shared understanding of the market and creating systems to learn from experience (both internal and external) while there is still time to change course.

Drug launches are hard. They are also predictable. By identifying weaknesses early, pharma companies can improve how they prioritize resources and adapt their strategies before launching… and not just after.

The post Why 60% of Drug Launches Fail appeared first on World of DTC Marketing.

When EMRs were first introduced, the vision was compelling. Digital records would improve care coordination, reduce medical errors, lower costs, and provide clinicians with immediate access to patient information. While EMRs successfully digitized healthcare information, they also introduced new challenges—expanding documentation requirements, creating increasingly complex workflows, and forcing clinicians to spend more time with keyboards than with patients.

Artificial intelligence (AI) presents an opportunity to fulfill the vision we originally had for EMRs. AI is not a replacement for the EMR. Instead, it has the potential to fundamentally transform how clinicians interact with it.

The Dream Versus the Reality

When hospitals and health systems began implementing EMRs, the expected benefits included:

• Better clinical decision-making
• Elimination of duplicate documentation
• Seamless information exchange
• Fewer medical errors
• Improved population health management
• Streamlined operational workflows

To be fair, EMRs have delivered meaningful improvements. Clinicians can access patient information faster than ever before. Computerized physician order entry has reduced many prescribing errors, and clinicians now have unprecedented amounts of clinical information available at the point of care.

Yet those gains have come with unintended consequences, including:

• Physician burnout
• Expanding documentation requirements
• Fragmented and inefficient clinical workflows

One of the most common frustrations clinicians express is that today’s EMRs seem optimized for billing rather than patient care. Although improving care was always the objective, many clinicians feel the technology has had the opposite effect.

AI Changes the EMR–Clinician Relationship

Historically, clinicians have been forced to adapt their workflows to meet the needs of the EMR. AI has the potential to reverse that dynamic. Instead of requiring clinicians to navigate dozens of screens to locate relevant information, AI can surface the right information at the right time. Instead of documenting every patient encounter manually, AI can generate clinical notes automatically. Instead of clicking through menus to answer clinical questions, clinicians can simply ask conversational questions and receive contextual responses.

The EMR remains the system of record. AI becomes the intelligent interface.

EMRs Store Data. AI Unlocks Clinical Intelligence.

EMRs have become exceptionally good at storing information. They have been far less successful at helping clinicians interpret and act upon that information. By layering AI capabilities on top of existing EMRs, healthcare organizations can:

• Automatically summarize complex patient histories
• Highlight clinically relevant trends
• Identify gaps in care
• Surface critical laboratory results and documentation
• Recommend evidence-based treatment options
• Detect potentially harmful medication interactions or changes
• Improve care coordination across multidisciplinary teams

In short, while EMRs capture data, AI helps transform that data into actionable clinical intelligence.

Reducing the Documentation Burden

Perhaps no aspect of the EMR frustrates physicians more than documentation. After a full day of patient care, many clinicians spend hours completing notes and administrative documentation.

AI-powered ambient documentation offers a fundamentally different approach.

By listening to conversations between clinicians and patients, AI can automatically generate structured clinical documentation. Physicians remain responsible for reviewing and approving the final documentation, but much of the manual work disappears. The value extends beyond efficiency.

Less time documenting means more time engaging with patients—and less time completing charts after hours.

Unlocking the Hidden Value of Clinical Data

Healthcare organizations have spent decades collecting enormous volumes of clinical data. Since the adoption of EMRs, that information has accumulated in both structured and unstructured formats. Unfortunately, much of it remains underutilized. AI changes that equation.

Its ability to analyze vast datasets allows healthcare organizations to extract insights that were previously impossible to generate manually.

Applications include:

• Population health management
• Predicting patients at risk for clinical deterioration
• Improving operational efficiency through predictive analytics
• Accelerating revenue cycle processes
• Enhancing quality measurement and reporting
• Advancing clinical research

EMRs helped healthcare organizations collect data.

AI can finally help organizations put that data to work.

AI Is Not a Silver Bullet

Despite its promise, AI is not a cure-all. Healthcare organizations must address several critical challenges before AI can be deployed responsibly and at scale, including:

• Data quality and standardization
• Interoperability across systems
• Governance and regulatory compliance
• Algorithm transparency
• Patient privacy
• Cybersecurity
• Clinical validation and human oversight

Strong governance will be essential to ensure AI systems remain transparent, reliable, and aligned with clinical best practices. Most importantly, AI should integrate naturally into existing clinical workflows rather than requiring clinicians to learn entirely new ways of working.

The Future of Electronic Medical Records

The EMRs of tomorrow will probably look remarkably similar to those we use today. Healthcare organizations are unlikely to replace their enterprise EMR platforms with entirely new AI-native systems. Instead, AI will increasingly be layered on top of existing platforms, making them dramatically more intelligent.

Future EMRs will:

• Answer clinical questions conversationally
• Generate documentation automatically
• Anticipate clinicians’ information needs
• Coordinate administrative tasks
• Improve patient communication
• Continuously learn from organizational data

Rather than navigating endless screens, clinicians will receive the information they need precisely when they need it. Instead of dividing their attention between patients and computer screens, they can devote more of their focus to what matters most—the patient sitting in front of them.

Bringing It All Together

When healthcare leaders embraced electronic medical records, their goal was never simply to replace paper with digital files. The objective was to make healthcare:

• Smarter
• Safer
• More connected

That vision remains just as relevant today. By augmenting EMRs with artificial intelligence, healthcare organizations have the opportunity to:

• Give clinicians more time with patients
• Reduce physician burnout
• Improve clinical decision-making
• Enhance quality and patient outcomes
• Lower administrative costs

For the first time since EMRs became mainstream, we have technology capable of delivering on the original promise of digital healthcare. The future of the EMR isn’t about replacing it. It’s about making it intelligent.

The post Can AI Finally Deliver on the Promise of Electronic Medical Records? appeared first on World of DTC Marketing.

Doctors are no longer raising awareness for brands; patients are. Physicians are often playing catch-up to educate patients on options. This fundamentally changes the marketing equation. 

Pharma Has the Wrong Funnel Topology

Most pharma marketers are still optimizing for old-school marketing metrics such as impressions, frequency, SOV, click-through rates, and website visits. These are GREAT measures for things you POST. They don’t help you understand how your brand showed up (or didn’t show up) in the hours and conversations that came before step 1 above.

The new patient journey looks less like this: symptom awareness > Google > Reddit > YouTube > ChatGPT > patient advocacy group > find a specialist > doctor appointment > Insurance research > Second opinion and more. Attributing a website visit or content download to a single doctor visit doesn’t capture the full scope of this journey.

 Competitive Advantage is Now AI Visibility

Billions of questions are being asked of AI engines daily:

1ne: “What medicines treat arthritis?” 

2wo: “Drug A vs Drug B, which is better?”

3hree: “What are the side effects of Drug C?” 

4our: “What questions should I ask my doctor?” 

AI isn’t stealing patients from search engines. AI is an additional “layer” of healthcare discovery. If your clinical evidence, marketing collateral, and website aren’t built in a way that allows AI to “see” it and reference it accurately, you’re going invisible on one of the largest growth information channels in history. SEO won’t cut it. Unless you build for answer engines, you’ll be evaporating competitive advantage before the game even begins. 

Trust Will Become the Ultimate Marketing KPI: Healthcare = Trust, Pharma Marketing = Attention

Attention rarely buys trust (at least in healthcare). But things are starting to change. Today, patients are starting to reward brands who: educate vs. persuade, acknowledge what they don’t know, empathize, simplify complex topics, and provide trustworthy resources

Here’s a tighter, more LinkedIn-native version with improved flow, stronger transitions, and cleaner formatting while preserving your core ideas.

The brands that sell the least may ultimately earn the most.

Because trust—not promotion—is becoming pharma’s most valuable marketing asset.

And trust drives:
• Patient adherence
• Physician confidence
• Long-term brand value

Trust is the new marketing currency.

Better Marketing Isn’t About Better Ads. It’s About Better Questions.

Stop asking:

“How do we get more impressions?”

Start asking:

“What questions are patients too afraid to ask?”

Instead of:

“How do we increase CTR?”

Ask:

“Where do patients feel uncertain during the treatment journey?”

And then ask:

“How can we eliminate that uncertainty?”

Don’t market to patients.

Solve patients’ problems.

AI Won’t Replace Pharma Marketers. Content-Only Marketers Will Become Irrelevant.

The marketers who thrive won’t simply create blog posts.

They’ll become:

• Insight detectives who uncover unmet patient needs.
• Translators who turn complex medical evidence into understandable patient resources.
• Experience designers who map content to real patient journeys.
• Trust builders who lead with empathy.
• Orchestrators who connect commercial, medical, digital, and regulatory teams.

AI will become exceptionally good at producing content. What it cannot easily replicate is human judgment. It doesn’t understand FDA regulations, scientific nuance, patient psychology, or the ethical tradeoffs that define pharmaceutical marketing. As AI creates more content, human expertise becomes more—not less—valuable.

Welcome to Pharma Marketing 2.0

Tomorrow’s marketers will:

• Build content for AI systems and human audiences.
• Measure educational impact alongside marketing performance.
• Bring commercial, digital, medical, and regulatory teams together much earlier.
• Treat patient intelligence with the same importance as market intelligence.
• View trust as a strategic asset—not an intangible outcome.

Success won’t necessarily require larger budgets. It will require a deeper understanding.

One Question Every Pharma Marketer Should Ask

Imagine every patient entering your therapeutic area spends 30 minutes talking with an AI assistant before seeing a physician. Could your brand confidently say that the AI is accurately representing your science, evidence, and approved messaging? If you’re not confident in that answer, your competitors have an opportunity. Every day that gap remains, AI continues learning—from whatever information is available. That information may be incomplete, outdated, or simply not yours.

The playing field is shifting now

AI is already narrowing the information gap between patients and physicians in ways our industry has discussed for years. If pharma marketers want to remain relevant, we can’t simply create more content. We need to help AI understand our science as accurately as we do.

The post The Pharma Marketing Playbook is Over. AI Didn’t Do It. Patients Did. appeared first on World of DTC Marketing.

Business Model: Patient-First Prescription Cooperative (PPC)

Core Idea

Create a membership-based organization that purchases medications directly from manufacturers (or licensed wholesalers), contracts with independent pharmacies, and passes savings to members with a fixed, transparent markup. The cooperative functions similarly to a warehouse club combined with a pharmacy benefit manager (PBM), but without rebate incentives.

Revenue Model

Revenue comes from four predictable sources:

• Monthly membership fee ($5–15/month)
• Small transparent markup (5–10%) on medications
• Employer-sponsored memberships
• Administrative fees for medication management services

No revenue is earned from manufacturer rebates.

How It Saves Money

1ne. Eliminate PBM Rebates

Today’s system often works like this:

Manufacturer → PBM → Insurance → Pharmacy → Patient

Every intermediary may receive fees or rebates. Instead:

Manufacturer → Cooperative → Pharmacy → Patient

This removes several layers of cost.

2wo. Transparent Pricing

Every prescription would display:

• Acquisition cost
• Distribution cost
• Pharmacy dispensing fee
• Cooperative margin

Example:

Manufacturer price: $22

Shipping/storage: $3

Pharmacy fee: $8

Co-op margin: $2

Final price:
$35

Instead of the same drug costing anywhere from $35–120 depending on insurance.

3hree. Direct Manufacturer Contracts

The cooperative negotiates directly with manufacturers based on total purchasing volume.

Manufacturers benefit because:

• lower marketing costs
• predictable demand
• guaranteed payment
• reduced PBM negotiations

4our. Generic First

Clinical pharmacists automatically recommend FDA-approved generics whenever appropriate.

Savings often exceed 80%.

5ive. Subscription Medications

For chronic illnesses:

• diabetes
• hypertension
• cholesterol
• asthma

Patients pay a monthly subscription. Example: $45/month. Unlimited eligible generic medications. Free mail delivery. Medication reminders. Pharmacist consultations. This smooths costs for patients while creating recurring revenue.

Technology Platform

A mobile app would include:

• Price comparison
• Prescription transfer
• Medication adherence reminders
• Automatic refill scheduling
• Drug interaction alerts
• Telepharmacy consultations
• Prior authorization assistance

AI Component

AI could:

• Recommend lower-cost therapeutic equivalents
• Identify manufacturer assistance programs
• Predict medication adherence risks
• Suggest 90-day fills when economical
• Optimize inventory purchasing

Additional Revenue Opportunities

Instead of increasing drug prices, the company could sell value-added services:

• Medication therapy management
• Employer wellness programs
• Chronic disease coaching
• Telehealth visits
• Pharmacogenomic testing
• Home delivery

Employer Partnership

Employers could pay: $8–12 per employee per month. Employees receive:

• discounted prescriptions
• free generics
• pharmacist access
• home delivery

Employers benefit through lower healthcare spending and reduced absenteeism.

Manufacturer Incentives

Manufacturers gain:

• guaranteed purchase volume
• lower customer acquisition costs
• predictable forecasting
• faster payment
• direct access to patient demand

Instead of spending heavily on rebates and marketing, they compete on transparent pricing.

Regulatory Advantages

The cooperative could operate as a licensed pharmacy network while complying with existing federal and state pharmacy regulations. It could also leverage:

• 340B partnerships where appropriate
• value-based purchasing agreements
• biosimilar substitution
• electronic prescribing integration
• Interstate mail-order pharmacy licensing

Example Economics

For a drug with a traditional retail price of $120:

Challenges

The model would need to overcome several hurdles:

• PBM and insurer resistance due to disrupted revenue streams.
• Difficulty negotiating favorable prices without sufficient purchasing volume in the early stages.
• State-by-state pharmacy licensing and compliance requirements.
• Integration with insurance plans for patients who want to use benefits rather than cash pricing.
• Capital requirements for inventory, technology, and distribution.

Long-Term Vision

Over time, the cooperative could evolve into a healthcare platform that combines prescription fulfillment, telehealth, chronic disease management, and preventive care. By scaling purchasing power and maintaining transparent pricing, it could lower medication costs while generating sustainable revenue through memberships and service fees rather than hidden markups.

The key differentiator is aligning financial incentives with affordability: the organization succeeds by increasing membership, improving medication adherence, and reducing overall healthcare costs—not by raising the prices patients pay for prescriptions.

The post Could This Model Work For Lowering Prescription Drug Costs? appeared first on World of DTC Marketing.

They Start With the Patient, Not the Product

Average marketers often begin with the brand’s key messages and work backward. Exceptional marketers start by asking different questions:

• What is this patient experiencing?
• What barriers keep them from seeking treatment?
• What misconceptions exist about the condition?
• What emotional journey are they on?

When campaigns are built around these insights, the messaging feels authentic rather than promotional. Patients are more likely to pay attention because they recognize themselves in the story.

They Build Trust Before They Build Demand

Healthcare is unlike almost any other industry. Consumers are making deeply personal decisions that affect their health, finances, and quality of life. Trust isn’t a nice-to-have—it’s the foundation of every successful campaign.

Strong DTC marketers know that credibility comes from transparency, balanced education, and realistic expectations. They don’t promise miracles. They help patients understand their options and encourage meaningful conversations with healthcare professionals. Ironically, this approach often creates stronger long-term brand performance than aggressive promotional tactics.

They Think Beyond Campaign Performance

Clicks, impressions, and prescription lift matter. Every marketer should measure performance. But outstanding marketers also ask questions that dashboards can’t easily answer. Did patients better understand their condition? Did they recognize symptoms they had previously ignored? Did they feel empowered to speak with their physician? Did the campaign reduce stigma or misinformation?

These outcomes may be more difficult to quantify, but they represent lasting value for both patients and brands.

They Respect the Complexity of Healthcare

Healthcare decisions rarely result from a single advertisement. Patients may spend weeks researching online, talking with family members, consulting specialists, comparing treatment options, and navigating insurance coverage before beginning therapy.

Great marketers understand this journey isn’t linear. Instead of trying to force a quick conversion, they design experiences that support patients at multiple stages—from disease awareness to diagnosis, treatment initiation, and long-term adherence.

They Collaborate Across the Organization

The strongest DTC marketers aren’t working in isolation. They regularly partner with medical affairs, legal, regulatory, market access, patient advocacy, analytics, and commercial teams. These collaborations lead to campaigns that are not only compliant but also more relevant and impactful. The most effective ideas often emerge when different perspectives come together around a shared goal: improving the patient experience.

They See the Brand as Part of a Larger Mission

Of course, brands exist to generate business results. Pharmaceutical companies invest billions of dollars in research and development, and successful commercialization enables future innovation. But the most respected DTC marketers recognize that commercial success and patient impact are not competing priorities.

When marketing genuinely educates, removes barriers to care, and helps appropriate patients seek treatment, everyone benefits. Patients receive better information. Healthcare providers have more informed conversations. Brands earn trust rather than simply capturing attention. That’s sustainable marketing.

They Learn From People Who Have Successfully Launched Brands

Some of the smartest and most experienced pharma marketers are either being forced out of the industry due to ageism or have left and can’t get hired by other companies because of closed-door pharma marketing hiring practices. Their years of experience are invaluable, but too many marketers today think they know better and are afraid to ask for help or to be shown up by someone who may be smarter. Believe me, it’s happening all over pharma.

The Difference Is Mindset

The difference between a good pharma DTC marketer and a great one isn’t creativity alone. It isn’t media strategy or data analytics, although those skills certainly matter. The difference is perspective. One marketer sees a campaign as a vehicle to grow a brand.

The other sees the brand as a vehicle to improve patients’ lives while achieving business objectives. That shift in thinking changes every decision—from audience research and creative development to measurement and optimization.

At the end of the day, the most successful pharma brands are often built by marketers who remember that behind every prescription is a person looking for answers. When marketers lead with empathy, education, and trust, business results tend to follow naturally.

The post What Makes a Great Pharma DTC Marketer? It’s Bigger Than the Brand appeared first on World of DTC Marketing.

She had gone through three weeks of interviews for this role at a leading biotech company, including over 18 phone interviews and a presentation. Then the silence. Nothing for over two weeks, and then the short email: “We have decided to move on with a different candidate.” Unfortunately, this is the norm with pharma. Your background doesn’t really matter; your ability to do the job doesn’t matter. What matters is: “Does she fit in?” and “Do I feel threatened by her?” This highlights the challenges in hiring at Pharma.

Make no mistake: the refusal of most pharma companies to hire experienced and knowledgeable people with a lot of experience is leading pharma companies into trouble.

Addressing these issues can streamline the process of hiring at Pharma, ensuring that the best candidates are not overlooked due to subjective biases.

The High Stakes of Every Hire

A poor hiring decision isn’t just expensive—it can have regulatory, financial, and even patient safety consequences. Whether the role is in research, manufacturing, quality assurance, regulatory affairs, or sales, companies want to ensure they’re hiring someone who can operate in a highly regulated environment. A level of scrutiny makes sense. But it doesn’t explain why the process often feels painfully inefficient and biased.

Too Many Decision Makers

One of the biggest obstacles is the number of people involved. A candidate might interview with:

• The hiring manager
• Team members
• Department directors
• Human Resources
• Cross-functional partners
• Senior leadership

Every stakeholder has a voice, and coordinating schedules alone can add weeks to the timeline. By the time everyone agrees, the strongest candidates may have already accepted another offer.

Internal Processes Become the Enemy

Large pharma companies often rely on complex HR systems designed to ensure consistency across thousands of employees. Ironically, these systems can create bottlenecks. Job requisitions require multiple approvals. Compensation packages move through committees. Recruiting teams coordinate with HR business partners, finance, legal, and department heads. Each approval may take only a day or two—but stack enough of them together, and a hiring process can stretch into months.

The Candidate Experience Suffers

The unfortunate consequence is that candidates often feel forgotten. Long periods of silence create uncertainty. Multiple interview rounds become repetitive. Applicants invest significant time preparing presentations and meeting new interviewers without receiving meaningful feedback.

For many professionals, the hiring process becomes more exhausting than the job itself.

Are Companies Looking for Fit or Someone Who Can Excel In The Job

Another challenge is the pursuit of someone who “fits”. They don’t want independent thinkers; they want people to just follow orders and do what they are told. Rather than hiring someone who meets 90 percent of the requirements and can grow into the role, organizations sometimes continue searching for someone who checks every imaginable box. Meanwhile, critical positions remain vacant, workloads increase for existing employees, and projects are delayed.

Fit is the enemy of progress.

Technology Hasn’t Solved the Problem

Artificial intelligence and applicant tracking systems promised faster recruiting. Instead, they’ve often introduced new frustrations. Qualified candidates are filtered out because their résumés don’t match specific keywords. Automated systems reject applicants before a hiring manager ever reviews their experience.

Technology should support human judgment—not replace it.

There’s a Better Way

Pharma companies don’t need to compromise quality to improve hiring. Organizations could:

• Reduce unnecessary interview rounds.
• Communicate with candidates more consistently.
• Empower hiring managers to make faster decisions.
• Focus on potential as well as experience.
• Eliminate redundant approval steps.

These changes would improve the candidate experience while helping companies secure top talent before competitors do.

The pharma industry is built on science, precision, and risk management. Those values are essential when developing medicines—but they shouldn’t make hiring unnecessarily complicated. A thoughtful hiring process is important. An endlessly prolonged one benefits no one.

The companies that learn to combine rigorous evaluation with speed, transparency, and respect for candidates will have a significant competitive advantage. In a market where talented professionals have options, hiring efficiently isn’t just good HR—it’s good business.

The post Why Is Hiring at Pharma Companies So Convoluted? appeared first on World of DTC Marketing.

When I got the call from a potential client, she said, “You’re the guy who writes about working in pharma,” to which I replied, “Yes, I do”. She then went on to say that there is a minority within most pharma companies that really want to focus on patients who need help, but that today it’s hard because everything is ROI driven. She and her company are now my clients.

Working in Pharma is not just about the products; it’s about the people who benefit from them.

Most people working in pharma companies are several steps removed from the patient. Whether you’re in marketing, medical affairs, sales, market access, regulatory, manufacturing, analytics, or operations, you may never meet the people whose lives are changed by your work. That distance can make your impact feel abstract. But it doesn’t make it any less real. Understanding the significance of Working in Pharma can bridge that gap and lead to a more meaningful connection.

Every Breakthrough Is Built by Thousands of People

When a new therapy reaches a patient, it’s easy to celebrate the scientist who discovered it or the physician who prescribed it. What we don’t see are the thousands of professionals whose work made that moment possible. Clinical researchers recruited patients and managed studies. Manufacturing teams ensured every dose met rigorous quality standards. Regulatory specialists navigated years of complex submissions. Medical affairs translated scientific evidence into clinical understanding. Supply chain teams delivered medicine where it was needed. Commercial teams educated healthcare professionals about appropriate use.

None of these roles alone changes a patient’s life. But together, they can.

The Invisible Moments Matter Most

Most patients never know who helped bring their medicine to market. They won’t know who created educational materials that helped a physician recognize a treatment option. They won’t know who optimized manufacturing to prevent shortages.

They won’t know who identified an unmet need through market research that ultimately shaped future research priorities. These contributions rarely make headlines. But patients experience their effects every day.

Marketing Isn’t Just About Promotion

Marketing in pharma is often misunderstood. Done poorly, it becomes noise. Done well, it becomes education. The best pharma marketers help physicians understand complex data, help patients recognize treatment options, and help healthcare systems adopt innovations responsibly.

When marketing is grounded in evidence, ethics, and patient outcomes, it serves an important purpose: connecting the right therapy with the right patient at the right time.

That’s not just good business. It’s good healthcare.

Success Has Two Bottom Lines

Every pharma company has financial objectives. They have to. Drug discovery is extraordinarily expensive, development can take more than a decade, and only a small fraction of compounds ever become approved medicines. Profit enables continued investment in research, manufacturing, and future innovation. But the best organizations understand there is another measure of success.

Did patients live longer? Did they avoid hospitalization? Did they regain the ability to work, travel, or spend time with family? Did they experience a better quality of life?

When commercial success and patient benefit align, everyone wins.

Remember the Person Behind the Prescription

It’s easy to think in terms of brands, market share, launches, and quarterly results. It’s harder—but far more meaningful—to remember that every prescription represents a person. Someone hoping to control their diabetes. Someone fighting cancer. Someone trying to breathe more easily. Someone managing depression well enough to return to work. Someone who simply wants another year with their grandchildren.

Those are the real outcomes behind every dashboard metric.

Your Role Matters More Than You Think

Not everyone discovers the next breakthrough therapy. Not everyone treats patients in a clinic. But everyone in the pharma ecosystem contributes to making those moments possible. Whether you improve a manufacturing process, analyze clinical data, build an educational campaign, negotiate market access, or answer questions from healthcare professionals, you’re part of a much larger mission.

You may never shake the hand of the patient whose life was changed because of your work. But that doesn’t mean they aren’t out there. Sometimes the most meaningful contributions are the ones you’ll never see. And perhaps that’s the best reminder of all: helping patients isn’t always about being visible. Often, it’s about ensuring that when someone needs a treatment, it is safe, effective, available, and understood. If your work helps make that happen, then yes—you really are making a difference.

The post Can You Really Make a Difference Working in Pharma? The Answer Is More Personal Than You Think appeared first on World of DTC Marketing.

Why Doctors and Patients Believe Coverage Should Be Automatic

Physicians spend years training to diagnose illnesses and recommend treatments. Their primary responsibility is to the patient sitting in front of them—not to an insurance company’s budget. From this perspective, denying a physician’s recommendation can appear to interfere with the doctor-patient relationship. Delays caused by prior authorization have been linked to postponed care, increased administrative burden, and physician burnout.

According to the American Medical Association’s 2024 Prior Authorization Survey:

• Nearly all physicians reported that prior authorization delays patient care.
• More than one-third said prior authorization had led to a serious adverse event for one of their patients.
• Physicians reported spending an average of nearly 13 hours per week on prior authorization-related activities.

These findings help explain why many clinicians advocate for major reforms—or even the elimination—of prior authorization for many services.

Why Insurers Say “No”

Insurance companies argue that simply approving every request would make health care dramatically more expensive while exposing patients to unnecessary or unproven treatments.

Health insurers generally deny requests for several reasons:

1ne. The treatment is not medically necessary.

Medical necessity is usually defined using evidence-based clinical guidelines developed by specialty societies and independent organizations. If research shows a treatment provides little benefit for a patient’s condition, insurers may decline coverage.

2wo. Lower-cost alternatives exist.

If two treatments produce similar outcomes, insurers often require patients to try the less expensive option first, a practice known as step therapy. For example:

• Using a generic medication before an expensive brand-name drug.
• Trying physical therapy before elective spinal surgery when clinically appropriate.

3hree. The treatment is experimental.

Many promising therapies reach physicians before strong clinical evidence demonstrates they are safe and effective. Insurers generally wait until sufficient evidence exists before routinely covering them.

4our. Fraud and overutilization.

Health care fraud remains a major financial problem. The National Health Care Anti-Fraud Association estimates that financial losses from health care fraud exceed tens of billions of dollars annually, with some estimates placing losses above $100 billion per year when waste and abuse are included. Without utilization review, insurers argue inappropriate billing and unnecessary procedures would become significantly more common.

What the Data Says About Denials

Contrary to popular perception, most medical claims are paid. Industry data consistently show that more than 95% of in-network medical claims are paid, although rates vary by insurer and type of service. Prior authorization affects only a subset of services—typically expensive imaging, specialty medications, surgeries, and certain hospital procedures. Among requests requiring prior authorization:

• Many are approved immediately.
• Others receive approval after additional documentation.
• A relatively small percentage are ultimately denied.

Interestingly, appeals often succeed. Government reports examining Medicare Advantage plans have found that a substantial share of initially denied requests that patients or providers appealed were eventually approved. This suggests that while some denials are appropriate, others result from incomplete documentation, administrative errors, or overly restrictive application of coverage policies.

What Would Happen if Everything Were Approved?

Imagine a health insurance system where every physician request was automatically covered. There would likely be several consequences.

Costs would increase.

Health spending in the United States already exceeds 17% of Gross Domestic Product (GDP)—far higher than in other developed countries. If every requested imaging study, surgery, biologic medication, genetic test, and experimental therapy were approved without review, premiums would almost certainly rise substantially.

Variation in physician practice would become more expensive.

Research consistently shows that physicians often recommend different treatments for similar patients. Automatic approval would remove one mechanism for standardizing care around evidence-based guidelines.

Innovation might accelerate.

On the positive side, patients could gain faster access to new therapies, and physicians would spend less time navigating administrative requirements.

The Real Question Isn’t “Approve Everything”

The debate should not be framed as choosing between unlimited approvals and frequent denials Instead, policymakers should ask:

• Are coverage decisions based on current scientific evidence?
• Are decisions made quickly enough to avoid harming patients?
• Are physicians given a fair opportunity to appeal?
• Are insurers transparent about why requests are denied?
• Can artificial intelligence and electronic health records reduce paperwork while preserving appropriate oversight?

A Better Balance

Most Americans agree on two principles: Patients should receive medically necessary care without unnecessary delays. Health care resources should be used responsibly to keep coverage affordable. Those goals are not mutually exclusive.

Health insurers have legitimate reasons to review expensive or experimental treatments. At the same time, physicians should not spend hours each week battling administrative barriers, and patients should not experience avoidable delays for evidence-based care. The challenge is designing a system in which utilization management protects patients and controls costs without becoming an obstacle to timely, appropriate treatment.

Rather than asking whether insurers should approve every request, the better question is this: Can we build a system where the right patients receive the right care at the right time—with as little bureaucracy as possible? That is a goal both patients and insurers should be able to support.

The post Why Health Insurers Don’t Approve Every Treatment a Doctor Recommends? appeared first on World of DTC Marketing.

Ah, the good old days. Pharma digital agencies were everywhere as pharmaceutical companies recognized the importance of digital. Today, they’re rare. They have been replaced by people like me (20+ years in digital) and have brought expertise in-house, or they are relying on their ad agencies to integrate digital.

I know some very good, smart, digital pharma marketing people at agencies. We learned from each other and did things that would drive regulatory people off a cliff, like allowing visitors to comment on a health condition (PMDD). Most of them are retired or they are working on other projects besides digital. It’s a shame because pharma desperately needs help in digital strategies.

Few agencies still identify themselves primarily as “digital agencies.” Many of the sector’s best-known firms have been acquired, consolidated, or repositioned. Those that remain independent increasingly describe themselves as commercialization partners, customer experience firms, AI consultancies, or integrated healthcare marketing agencies. The obvious question is: What happened? The answer is not that digital agencies failed. Rather, digital itself ceased to be a differentiator.

The Era When Digital Was the Product

Between roughly 2005 and 2018, pharmaceutical companies faced a massive capability gap. The industry’s commercial model was shifting away from traditional sales representatives toward increasingly digital interactions with healthcare professionals and patients. Regulatory requirements made healthcare marketing significantly more complex than consumer advertising, creating demand for agencies that understood FDA promotional regulations, medical-legal review, adverse event reporting, and privacy requirements. Digital specialists filled that void. Their services included:

• Corporate and brand websites
• Physician education portals
• Patient support platforms
• Customer relationship management (CRM)
• Email marketing
• Banner advertising
• Mobile applications
• Interactive sales presentations
• Analytics and measurement
• Early omnichannel strategy

At the time, these capabilities represented specialized expertise. Today, they represent baseline expectations.

Case Study: Intouch Group

Perhaps no company better represents the rise of pharmaceutical digital agencies than Intouch Group. Founded in the late 1990s, Intouch became one of healthcare’s largest independent digital marketing agencies. While many competitors remained focused on execution, Intouch steadily expanded into strategy, analytics, technology, media, customer experience, and commercialization support.

Its evolution mirrored the industry’s own transformation. By the time EVERSANA acquired Intouch Group in 2022, the acquisition was not simply about adding creative capabilities. It was about creating an integrated commercialization platform that combined consulting, medical affairs, market access, patient services, technology, and marketing under a single organization.

The message was unmistakable: Marketing had become only one component of commercialization.

Case Study: Digitas Health

Digitas Health followed a different—but equally revealing—path.

Originally recognized for digital innovation in healthcare marketing, the agency eventually became part of Publicis Health, where its digital capabilities were integrated with media, strategy, creative development, behavioral science, analytics, and customer engagement. The word “digital” gradually became less important than the outcomes it enabled. Instead of promoting websites or applications, agencies increasingly emphasized customer experience, connected engagement, and measurable business performance.

Digital was no longer a department.

It became infrastructure.

Case Study: Razorfish Health

Razorfish Health experienced a similar evolution. Its early reputation centered on technology-enabled marketing innovation. Over time, however, the firm’s positioning expanded toward connected customer experiences, data, artificial intelligence, omnichannel orchestration, and personalized engagement. This reflects a broader market reality. Clients no longer purchase digital assets. They purchase business outcomes.

The Transformation of Publicis Health

The evolution of Publicis Health illustrates perhaps the industry’s clearest strategic shift. Rather than maintaining separate digital organizations that compete with traditional agencies, Publicis has increasingly organized its capabilities around integrated customer solutions. Creative, media, data science, technology, analytics, customer experience, behavioral science, and AI now operate together rather than independently. The distinction between “digital agency” and “agency” has largely disappeared.

Why Digital Agencies Lost Their Competitive Advantage

Several structural changes fundamentally altered the marketplace.

1ne: Digital Became Expected

The first and most obvious shift was that every agency became digital. Whether focused on advertising, medical communications, payer marketing, or public relations, agencies invested heavily in digital talent. The specialization disappeared.

2wo: Enterprise Technology Replaced Custom Development

Early digital agencies differentiated themselves by building proprietary websites, CRM integrations, mobile applications, and custom platforms. Today, pharma companies rely increasingly on enterprise ecosystems from providers such as Veeva Systems, Salesforce, Adobe, IQVIA, and Microsoft. Rather than building software from scratch, agencies configure existing platforms, integrate data, and optimize workflows. That work remains valuable. It is also less differentiated.

3hree: Consulting Entered Commercial Marketing

Management consultants recognized that pharma commercialization represented billions of dollars in strategic spending. Organizations such as Accenture, Deloitte, PwC, and Capgemini expanded beyond traditional consulting into customer experience, CRM implementation, analytics, AI, digital transformation, and marketing operations.

Agencies suddenly faced competitors capable of advising executive leadership while simultaneously implementing enterprise technology. Budget authority increasingly shifted toward enterprise transformation initiatives rather than standalone marketing campaigns.

4our: Procurement Changed Buying Behavior

Agency selection also became more centralized. Procurement organizations emphasized standardized pricing, global contracts, offshore delivery, utilization rates, and vendor consolidation. Large agency networks benefited from economies of scale. Smaller specialty agencies often found themselves competing on price rather than expertise.

5ive: AI Is Accelerating the Next Transformation

Artificial intelligence represents the latest—and perhaps most significant—inflection point. Generative AI is rapidly reducing the time required for:

• First-draft copywriting
• Content adaptation
• Banner production
• Localization
• Image generation
• Code development
• Personalization
• Basic analytics

Activities that once consumed hundreds of agency hours can increasingly be completed in minutes. This does not eliminate agencies. It fundamentally changes what clients value. Execution becomes commoditized.

Strategic thinking, scientific expertise, governance, data interpretation, and commercialization strategy become increasingly valuable. The agencies investing in AI-enabled workflows will likely enjoy significant productivity advantages over competitors that continue relying primarily on traditional production models.

Where Independent Agencies Can Still Win

Despite industry consolidation, opportunities remain substantial for independent healthcare agencies. In fact, independence may become an advantage. Large holding companies often struggle with organizational complexity, overlapping capabilities, and slower decision-making. Independent firms can move faster, adopt AI more aggressively, and specialize deeply in emerging commercial challenges.

Several areas remain particularly attractive:

AI governance for regulated marketing. Pharmaceutical companies need partners who understand both generative AI and FDA promotional requirements.

Launch commercialization. New product launches continue to demand integrated strategic support that combines market research, messaging, omnichannel engagement, analytics, and measurement.

Customer experience design. As healthcare professionals increasingly expect consumer-grade digital interactions, agencies capable of improving the end-to-end experience will remain in demand.

Data activation. Pharmaceutical organizations possess enormous amounts of commercial data but frequently struggle to translate it into actionable marketing decisions.

Medical and scientific storytelling. AI can generate content, but translating complex clinical evidence into compelling, compliant communications remains a distinctly human capability.

Specialization. Rare diseases, oncology, cell and gene therapy, diagnostics, digital therapeutics, and companion diagnostics each require expertise that generalist agencies often lack.

The Agency of the Future

The next generation of successful healthcare agencies will look very different from the digital agencies of the past. They will combine:

• Commercial strategy
• Scientific expertise
• Artificial intelligence
• Data engineering
• Customer experience
• Technology integration
• Analytics
• Behavioral science
• Regulatory knowledge
• Creative excellence

Digital will simply be assumed. Clients will increasingly evaluate agencies based on measurable commercial impact rather than production capabilities alone. The agencies that thrive won’t be those producing the most digital assets. They’ll be those helping pharma companies solve their most complex business problems.

Looking back, it is tempting to ask, “What happened to all the pharma digital agencies?” The better question is, “What happened to digital?” The answer is simple.

Digital stopped being a specialty.

It became the foundation upon which every successful healthcare agency now operates. The agencies that survived understood the need for transformation early. They evolved from digital vendors into strategic commercialization partners.

Those that did not were absorbed, consolidated, or left behind. The next decade will not be defined by who is most digital. It will be defined by who best combines science, technology, artificial intelligence, creativity, and commercial strategy to improve patient outcomes and business performance.

That is a much more demanding—and much more exciting—future for the healthcare agency business.

The post What Happened To Pharma Digital Agencies? appeared first on World of DTC Marketing.

The Central Argument

The report contends that recent federal legislation significantly reduced funding for Medicaid and the ACA while extending tax cuts elsewhere in the federal budget. According to the document, the consequences include:

• Nearly 15 million Americans projected to lose health insurance coverage.
• 2.5 million Medicaid recipients already losing coverage.
• ACA marketplace premiums increasing by an average of 114% after enhanced tax credits expired.
• Marketplace enrollment declining by 21.5%.
• Deductibles increasing by an average of 37%.
• Increased hospital closures, delayed care, and rising medical debt.

These are substantial claims that, if accurate, would represent one of the most significant disruptions to the U.S. health insurance system in decades.

Why Medicaid Matters

Medicaid covers approximately one in five Americans, including:

• Low-income families
• Children
• Pregnant women
• Seniors needing long-term care
• People with disabilities

Changes to eligibility rules, work requirements, or renewal procedures can quickly affect millions of beneficiaries. Even individuals who remain eligible sometimes lose coverage because of paperwork, documentation, or administrative hurdles. Supporters of stricter eligibility requirements argue they help preserve the program for those who qualify and reduce fraud and improper payments. Critics argue that these requirements often remove eligible people from coverage without meaningfully reducing costs.

The Impact of ACA Tax Credits

One of the report’s strongest assertions involves the expiration of enhanced ACA premium tax credits. These subsidies were originally expanded during the COVID-19 pandemic to make Marketplace insurance more affordable. Without them:

• Monthly premiums rise for many households.
• Some consumers choose less comprehensive plans.
• Others drop coverage entirely.
• Higher premiums may discourage younger and healthier people from enrolling, pushing costs even higher.

Health economists have long noted that premium subsidies play a major role in maintaining stable insurance markets.

Hospitals Feel the Pressure

Reduced insurance coverage doesn’t affect only patients. Hospitals—particularly rural hospitals and safety-net providers—depend heavily on Medicaid reimbursement. When more patients become uninsured:

• Emergency departments provide more uncompensated care.
• Financial margins shrink.
• Smaller hospitals become more vulnerable to closure.
• Communities lose access to nearby healthcare services.

Rural America is especially sensitive because many communities have only one hospital serving an entire region.

The Political Debate

Supporters of these policy changes argue that:

• Federal healthcare spending had become unsustainable.
• Medicaid should focus on the most vulnerable populations.
• Work requirements encourage employment and personal responsibility.
• Deficit reduction is necessary for long-term economic stability.

Opponents counter that:

• Healthcare is a basic necessity.
• Coverage losses increase preventable illness.
• Higher uninsured rates ultimately raise healthcare costs elsewhere in the system.
• Administrative barriers often remove eligible individuals from coverage.

Both sides agree healthcare spending is one of the largest federal budget challenges. They disagree sharply on how to manage it.

Looking Beyond the Headlines

The language in the Defend America Action report is intentionally persuasive, reflecting its role as a political advocacy document rather than a neutral policy analysis. Many of its factual claims—such as projected coverage losses and premium increases—can and should be evaluated against analyses from independent organizations, including the Congressional Budget Office, the Centers for Medicare & Medicaid Services, and nonpartisan health policy research groups.

For voters, employers, physicians, insurers, and patients, the larger question is not simply who is right politically. It is whether healthcare reforms improve access, affordability, and outcomes without creating unintended consequences.

Healthcare policy affects nearly every American family. Whether through Medicaid eligibility, ACA subsidies, insurance premiums, or hospital finances, policy decisions made in Washington have real-world consequences in doctors’ offices, emergency rooms, and household budgets.

As political campaigns intensify, Americans will hear competing narratives about healthcare reform. The most productive conversations will move beyond slogans and focus on evidence, transparency, and measurable outcomes—because regardless of politics, the ultimate goal should be a healthcare system that is both financially sustainable and accessible to those who need it most.

The post Health Care in Crisis? Separating Political Claims from Policy Reality appeared first on World of DTC Marketing.